At $594 Per Dose Gilead Sciences, Inc. (GILD) Hepatitis Drug Is Too Costly For Veterans Affairs Department


Gilead Sciences, Inc. (NASDAQ:GILD)‘s hepatitis C drug Sovaldi, which comes at a cost of $1,000 a pill, has proved to be a breakthrough that reduces treatment time to 12 weeks and at reduced risk compared to a year-long treatment option available. However, this heavily-priced therapy has raised concerns and criticisms across the U.S. by payers and consumer support groups.

To consider the impact of Sovaldi’s $84,000 12-week treatment cost, the Veterans Affairs Department provides this therapy only to the sickest patients who need it. The Department is the largest single provider of hepatitis C care in the U.S., which enabled it to negotiate more than 40% discount to the $594 per-dose price with Gilead.

VA and Hepatitis C Care

The Veterans Affairs Department added Sovaldi to its formulary in April 2014. It treated around 5,400 veterans at a cost of $370 million with Sovaldi in fiscal 2014, and has asked Congress for $1.3 billion to treat another 30,000 patients with Sovaldi and other new hepatitis C drugs.

But it would be “cost prohibitive” for the Veterans Health Administration to treat all of the 174,000 hepatitis C patients in its health system. Hence, the VA Department favors a conservative approach of reserving Sovaldi and Olysio only for those needing a transplant or with advanced liver disease. The VA has negotiated a price of $413 per pill of Olysio with Janssen Therapeutics.

The Pricing Concerns

Gilead Sciences, Inc. (NASDAQ:GILD) has also been accused by the U.S. lawmakers and advocates for significant price differences in overseas territories. A 12-week Sovaldi treatment costs $55,000 in Canada and $66,000 in Germany. Meanwhile, Gilead has also been reported of pursuing talks to make the generic versions available just for $2,000 in India.

Amid criticism, the company maintains that Sovaldi cures a life-threatening disease, eliminating the need for traditionally available long-term therapies for other chronic diseases and also saves significant post-operative expenses after liver transplants. The treatment is priced similar to year-long hepatitis C regimens.

Lisa Ray

Lisa Ray primarily covers Retail and Healthcare. Lisa Ray has completed her MBA (Finance) and an avid market tracker. She is a stock market analyst who closely tracks US markets along with other global markets like India. She has been expressing her views for years about markets and also advises various clients.

You may also like...

Read previous post:
dupont
Proxy Fight Begins At E I Du Pont De Nemours And Co (DD)

E I Du Pont De Nemours And Co (NYSE:DD)’s Board of Directors has not questioned management's accountability for repeated failures...

Close